Pityriasis versicolor: a review of pharmacological treatment options

Bibliography

• CRESPO EV, DELGADO FV: Malassezia species in skin diseases. Curr. Opin. Infect. Dis. (2002) 15(2):133–142.
   PubMedGoogle Scholar
• MIDGLEY G: The lipophilic yeasts: state of the art and prospects. Med. Mycol. (2000) 38(Suppl.):19–16.
   Google Scholar
• ••Provides a comprehensive review ofclassification of Malassezia yeast as well as discriminatory methods that help to determine individual species.
   Google Scholar
• BORELLI D, JACOBS PH, NALL L: Tinea versicolor: epidemiologic, clinical, and therapeutic aspects. J. Am. Acad. DermatoL (1991) 25(2 Pt 0:300–305.
   Google Scholar
• MELLEN LA, VALLEE J, FELDMAN SR, FLEISCHER AB Jr: Treatment of pityriasis versicolor in the United States. J. Dermatolog Treat. (2004) 15(3):189–192.
   PubMedGoogle Scholar
• ••An excellent assessment of frequency ofvisits and PV treatment in the US in the years 1990-1999.
   Google Scholar
• FAERGEMANN J: Pityrosporum species as a cause of allergy and infection. Allergy (1999) 54(5):413–419.
   PubMedGoogle Scholar
• ZUBER TJ, BADDAM K: Superficial fungal infection of the skin. Where and how it appears help determine therapy. Postgrad. Med. (2001) 109(1):117–120, 123–126, 131–132.
   Google Scholar
• GORDON MA: Lipophilic yeastlike organisms associated with tinea versicolor. J. Invest. Dermatol (1951) 17(5):267–272.
   PubMedGoogle Scholar
• GUPTA AK, COOPER EA, RYDER JE, NICOL KA, CHOW M, CHAUDHRY MM: Optimal management of fungal infections of the skin, hair, and nails. Am. J. Clin. Dermatol (2004) 5(4):225–237.
   PubMedGoogle Scholar
• SCHWARTZ RA: Superficial fungal infections. Lancet (2004) 364(9440):1173–1182.
   PubMedGoogle Scholar
• SOHNLE PG, COLLINS-LECH C: Relative antigenicity of P. orbiculare and C. albicans. J. Invest. Dermatol (1980) 75(3):279–283.
   PubMedGoogle Scholar
• ASHBEE HR, INGHAM E, HOLLAND KT, CUNLIFFE WJ: Cell-mediated immune responses to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrheic dermatitis and controls. Exp. Dermatol (1994) 3(3):106–112.
   PubMedGoogle Scholar
• BERGBRANT IM, ANDERSSON B, FAERGEMANN J: Cell-mediated immunity to Malassezia furfitr in patients with seborrhoeic dermatitis and pityriasis versicolor. Clin. Exp. Dermatol (1999) 24(5):402–406.
   PubMedGoogle Scholar
• NEUBER K, KROGER S, GRUSECK E, ABECK D, RING J: Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN gamma) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch. Dermatol Res. (1996) 288(9):532–536.
   PubMed Web of Science ®Google Scholar
• SOHNLE PG, COLLINS-LECH C: Cell-mediated immunity to Pityrosporum orbiculare in tinea versicolor. J. Clin. Invest. (1978) 62(1):45–53.
   PubMedGoogle Scholar
• WU YC, CHEN KT: Humoral immunity in patients with tinea versicolor. Dermatol (1985) 12(2):161–166.
   Google Scholar
• FAERGEMANN J: Antibodies to Pityrosporum orbiculare in patients with tinea versicolor and controls of various ages. J. Invest. DermatoL (1983) 80(2):133–135.
   PubMedGoogle Scholar
• STERNBERG TH, KEDDIE FM: Immunofluorescence studies in tinea versicolor. A preliminary report. Arch. Dermatol (1961)84:999–1003.
   PubMedGoogle Scholar
• MCGINLEY KJ, LANTIS LR, MARPLES RR: Microbiology of tinea versicolor. Arch. Dermatol (1970) 102(2):168–171.
   PubMedGoogle Scholar
• BURKE RC: Tinea versicolor: susceptibility factors and experimental infection in human beings. J. Invest. Dermatol (1961)36:389–402.
   PubMed Web of Science ®Google Scholar
• SILVA-LIZAMA E: Tinea versicolor. Int. J. Dermatol (1995) 34(9):611–617.
   PubMedGoogle Scholar
• CATTERALL MD, WARD ME, JACOBS P: A reappraisal of the role of Pityrosporum orbiculare in pityriasis versicolor and the significance of extracellular lipase. J. Invest. Dermatol (1978) 71(6):398–401.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, KOHLI Y, SUMMERBELL RC, FAERGEMANN J: Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med. Myed. (2001) 39(3):243–251.
   Google Scholar
• ••Examines whether the quantity andcomposition of Malassezia spp. at a given anatomical site in normal individuals differs from that of patients with various cutaneous dermatoses.
   Google Scholar
• TARAZOOIE B, KORDBACHEH P, ZAINI F et al.: Study of the distribution of Malassezia species in patients with pityriasis versicolor and healthy individuals in Tehran, Iran. BMC Dermatol (2004) 4(1):5.
   PubMedGoogle Scholar
• CRESPO-ERCHIGA V MARTOS AO, CASANO AV CRESPO-ERCHIGA A, SANCHEZ-FAJARDO F, GUEHO E: Mycology of pityriasis versicolor. J. Mycol. Med. (1999) 9:143–148.
   Google Scholar
• ••An excellent review of PV mycology.
   Google Scholar
• ASPIROZ C, ARA M, VAREA M, REZUSTA A, RUBIO C: Isolation of Malassezia globosa and M. sympodialis from patients with pityriasis versicolor in Spain. Mycopathologia (2002) 154(3):111–117.
   Google Scholar
• MAYSER P, GROSS A: IgE antibodies to Malassezia furfur, M. sympodialis and Pityrosporum orbiculare in patients with atopic dermatitis, seborrheic eczema or pityriasis versicolor, and identification of respective allergens. Acta Derm. Venereol (2000) 80(5):357–361.
   Google Scholar
• HATTORI M, OGAWA H, TAKAMORI K, GRITIYARANSON P, KOTARAJARAS R: De-(hypo)pigmentation mechanisms of the affected area of Pityriasis versicolor. Dermatol (1984) 11(1):63–66.
   Google Scholar
• TOSTI A, VILLARDITA S, FAZZINI ML: The parasitic colonization of the horny layer in tinea versicolor. J. Invest. Dermatol. (1972) 59(3):233–237.
   PubMedGoogle Scholar
• ••Provides evidence that hyperpigmented PVlesions exhibit increased stratum corneum turnover, and larger, singly distributed melanosomes.
   Google Scholar
• ALLEN HB, CHARLES CR, JOHNSON BL: Hyperpigmented tinea versicolor. Arch. Dermatol. (1976) 112(8):1110–1112.
   PubMedGoogle Scholar
• KARAOUI R, BOU-RESLI M, AL ZAID NS, MOUSA A: Tinea versicolor: ultrastructural studies on hypopigmented and hyperpigmented skin. Dermatologica (1981) 162(2):69–85.
   PubMedGoogle Scholar
• GALADARI I, EL KOMY M, MOUSA A, HASHIMOTO K, MEHREGAN AH: Tinea versicolor: histologic and ultrastructural investigation of pigmentary changes. Int. j Dermatol. (1992) 31(4):253–256.
   PubMedGoogle Scholar
• ••A well-conducted and presentedcomparative histopathological study between the hypo- and hyperpigmented skin lesions of PV and normal skin areas.
   Google Scholar
• DOTZ WI, HENRIKSON DM, YU GS, GALEY CI: Tinea versicolor: a light and electron microscopic study of hyperpigmented skin. J. Am. Acad. Dermatol (1985) 12(1 Pt 1):37–44.
   Google Scholar
• CHARLES CR, SIRE DJ, JOHNSON BL, BEIDLER JG: Hypopigmentation in tinea versicolor: a histochemical and electronmicroscopic study. Int. J. Dermatol. (1973) 12(1):48–58. A histochemical and electronmicroscopic study examining hypopigmentation of the skin in PV.
   Google Scholar
• MAYSER P, PAPE B: Decreased susceptibility of Malassezia furfur to UV light by synthesis of tryptophane derivatives. Antonie van Leeuzvenhoek (1998) 73(0315–319.
   PubMedGoogle Scholar
• MAYSER P, STAPELKAMP H, KRAMER HJ et al.: Pityrialactone- a new fluorochrome from the tryptophan metabolism of Malassezia furfur. Antonie van Leeuzvenhoek (2003) 84(3):185–191.
   PubMedGoogle Scholar
• BLUMENTHAL HL: Tinea versicolor of penis. Arch. Dermatol. (1971) 103(4):461–462.
   PubMedGoogle Scholar
• NAZZARO-PORRO M: Azelaic acid. J. Am. Acad. Dermatol. (1987) 17(6):1033–1041.
   PubMed Web of Science ®Google Scholar
• NAZZARO-PORRO M, PASSI S: Identification of tyrosinase inhibitors in cultures of Pityrosporum. J. Invest. Dermatol. (1978) 71(3):205–208.
   PubMedGoogle Scholar
• NAZZARO-PORRO M, PASSI S, PICARDO M, MERCANTINI R, BREATHNACH AS: Lipoxygenase activity of Pityrosporum in vitro and in vivo. J. Invest. Dermatol. (1986) 87(1):108–112.
   PubMedGoogle Scholar
• ••Provides evidence to suggest that thepresence of a significant amount of lipopercocides in skin lipids may play a role in the pathogenesis of skin alterations in PV.
   Google Scholar
• CHU AC: Comparative clinical trial of bifonazole solution versus selenium sulphide shampoo in the treatment of pityriasis versicolor. Dermatologica (1984) 169(Suppl.):181–186.
   Google Scholar
• FAERGEMANN J, FREDRIKSSON T: An open trial of the effect of a zinc pyrithione shampoo in tinea versicolor. Cutts (1980) 25(6):667, 669.
   Google Scholar
• VERMEER BJ, STAATS CC: The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo-controlled study. Dermatology (1997) 194(Suppl.):122–124.
   Google Scholar
• ROGERS CJ, COOK TF, GLASER DA: Diagnosing tinea versicolor: don't scrape, just tape. Pediatr. Dermatol. (2000) 17(1):68–69.
   PubMedGoogle Scholar
• COHEN MM: A simple procedure for staining tinea versicolor (M. furfur) with fountain pen ink. J. Invest. Dermatol. (1954) 22(1):9–10.
   PubMedGoogle Scholar
• SUNENSHINE PJ, SCHWARTZ RA, JANNIGER CK: Tinea versicolor: an update. Cutts (1998) 61(2):65–68.
   PubMedGoogle Scholar
• HERSLE K: Selenium sulphide treatment of tinea versicolor. Acta Derm. Venereol. (1971) 51(0:476–478.
   PubMedGoogle Scholar
• SANCHEZ JL, TORRES VM: Selenium sulfide in tinea versicolor: blood and urine levels. J. Am. Acad. Dermatol (1984) 11(2 Pt 1):238–241.
   Google Scholar
• KATSAMBAS A, RIGOPOULOS D, ANTONIOU C, ZACHARI A, FRAGOULI E, STRATIGOS J: Econazole 1% shampoo versus selenium in the treatment of tinea versicolor: a single-blind randomized clinical study. Int. j Dermatol. (1996) 35(9):667–668.
   PubMedGoogle Scholar
• KLIGMAN AM, LEYDEN JJ, STEWART R: New uses for benzoyl peroxide: a broad-spectrum antimicrobial agent. Int. J. Dermatol. (1977) 16(5):413–417.
   PubMedGoogle Scholar
• PRESTIA AE: Topical benzoyl peroxide for the treatment of tinea versicolor. J. Am. Acad. Dermatol (1983) 9(2):277–278.
   PubMedGoogle Scholar
• FAERGEMANN J, FREDRIKSSON T: Antimycotic activity of propane-1,2-diol (propylene glycol). Sabouraudia (1980) 18(3):163–166.
   PubMedGoogle Scholar
• FAERGEMANN J, FREDRIKSSON T: Propylene glycol in the treatment of tinea versicolor. Acta Derm. Venereol (1980) 60(1):92–93.
   PubMedGoogle Scholar
• CLAYTON R, DU VA, SAVAGE M: Double-blind trial of 1% clotrimazole cream and Whitfield ointment in the treatment of pityriasis versicolor. Arch. Dermatol. (1977) 113(6):849–850.
   PubMedGoogle Scholar
• BAMFORD JT: Treatment of tinea versicolor with sulfur-salicylic shampoo. J. Am. Acad. Dermatol. (1983) 8(2):211–213.
   PubMedGoogle Scholar
• FREDRIKSSON T, FAERGEMANN J: Double-blind comparison of a zinc pyrithione shampoo and its shampoo base in the treatment of tinea versicolor. Cutts (1983) 31(4):436–437.
   PubMedGoogle Scholar
• LANGE DS, RICHARDS HM, GUARNIERI J et al.: Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. (1998) 39(6):944–950.
   PubMedGoogle Scholar
• SAWN RC, HORWITZ SN: Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J. Am. Acad. Dermatol (1986) 15(3):500–503.
   PubMedGoogle Scholar
• ASTE N, PAU M, CORDARO CI, BIGGIO P: Double-blind study with fenticonazole or bifonazole lotions in pityriasis versicolor. Int. J. Clin. Pharmacol Res. (1988) 8(4):271–273.
   PubMedGoogle Scholar
• HAY RJ, ADRIAANS B, MIDGLEY G, ENGLISH JS, ZACHARY CB: A single application of bifonazole 1% lotion in pityriasis versicolor. Clin. Exp. Dermatol (1987) 12(4):315.
   PubMedGoogle Scholar
• •A well-conducted and reported clinical trial.
   Google Scholar
• MORA RG, GREER DL: Comparative efficacy and tolerance of 1% bifonazole cream and bifonazole cream vehicle in patients with tinea versicolor. Dermatologica (1984) 169(Suppl.):187–192.
   Google Scholar
• SOYINKA F: Bifonazole in the treatment of fungal skin infections in the tropics: a clinical and mycological study. Curr. Med. Res. Opin. (1987) 10(6):390–396.
   PubMed Web of Science ®Google Scholar
• DEL PALACIO HA, LOPEZ GS, IGLESIAS DL: Short course bifonazole therapy in pityriasis versicolor. Clin. Exp. Dermatol (1987) 12(4):270–272.
   PubMedGoogle Scholar
• ALCHORNE MM, PASCHOALICK RC, FORJAZ MH: Comparative study of tioconazole and clotrimazole in the treatment of tinea versicolor. Clin. Ther. (1987) 9(4):360–367.
   PubMedGoogle Scholar
• GIP L: The topical therapy of pityriasis versicolor with clotrimazole. Postgrad. Med. J. (1974) 50(Suppl.):159–160.
   Google Scholar
• •A well-conducted and reported clinical trial.
   Google Scholar
• CLAYTON YM, CONNOR BL: Comparison of clotrimazole cream, Whitfield's ointment and Nystatin ointment for the topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis. Br. J. Dermatol (1973) 89(3):297–303.
   PubMedGoogle Scholar
• SPIEKERMANN PH, YOUNG MD: Clinical evaluation of clotrimazole. A broad-spectrum antifungal agent. Arch. Dermatol (1976) 112(3):350–352.
   PubMedGoogle Scholar
• TANENBAUM L, ANDERSON C, ROSENBERG MJ, AKERS W: 1% sulconazole cream v 2% miconazole cream in the treatment of tinea versicolor. A double-blind, multicenter study. Arch. Dermatol (1984) 120(2):216–219.
   PubMedGoogle Scholar
• VICIK GJ, MENDIONES M, QUINONES CA, THORNE EG: A new treatment for tinea versicolor using econazole nitrate 1.0 percent cream once a day. Cutts (1984) 33(6):570–571.
   Google Scholar
• NASARRE J, UMBERT P, HERRERO E et al.: Therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of Pityriasis versicolor. Arzneimittelfbrschung (1992) 42(5A):764–767.
   Google Scholar
• HAROON TS, TAREEN MI, HAFIZ A, RIZWANA: An open study of tioconazole 1% dermal cream in patients with pityriasis versicolor. J. Pak. Med. Assoc. (1984) 34(12):361–362.
   PubMedGoogle Scholar
• RIGOPOULOS D, KATSAMBAS A, ANTONIOU C, POLYDOROU D, VLACHOU M, STRATIGOS J: Tinea versicolor treated with fluconazole shampoo. Int. J. Dermatol (1992) 31(9):664–665.
   PubMedGoogle Scholar
• PETRANYI G, RYDER NS, STUTZ A: Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science (1984) 224(4654):1239–1241.
   PubMedGoogle Scholar
• ASTE N, PAU M, PINNA AL, COLOMBO MD, BIGGIO P: Clinical efficacy and tolerability of terbinafine in patients with pityriasis versicolor. Mycoses (1991) 34(7-8):353–357.
   PubMedGoogle Scholar
• FAERGEMANN J, HERSLE K, NORDIN P: Pityriasis versicolor: clinical experience with Lamisil cream and Lamisil DermGel. Dermatology (1997) 194(Suppl.):119–121.
   Google Scholar
• PALACIO-HERNANZ A, GUARRO-ARTIGAS J, FIGUERAS-SALVAT MJ, ESTEBAN-MORENO J, LOPEZ-GOMEZ S: Changes in fungal ultrastructure after short-course ciclopiroxolamine therapy in pityriasis versicolor. Clin. Exp. Dermatol (1990) 15(2):95–100.
   PubMedGoogle Scholar
• CORTE M, JUNG K, LINKER U, MARTINI H, SAPP-BONCELET I, SCHULZ H: [Topical application of a 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor]. Mycoses (1989) 32(4):200–203.
   Google Scholar
• •A well-conducted and reported clinical trial.
   Google Scholar
• URCUYO FG, ZAIAS N: The successful treatment of pityriasis versicolor by systemic ketoconazole. J. Am. Acad. Dermatol. (1982) 6(1):24–25.
   PubMed Web of Science ®Google Scholar
• HAY RJ, MIDGELEY G: Short course ketoconazole therapy in pityriasis versicolor. Clin. Exp. DermatoL (1984) 9(6):571–573.
   PubMedGoogle Scholar
• SADEQUE JB, SHAHIDULLAH M, SHAH OR, KAMAL M: Systemic ketoconazole in the treatment of tinea versicolor. Int. J. Dermatol (1995) 34(7):504–505.
   PubMedGoogle Scholar
• •A well-conducted and reported clinical trial.
   Google Scholar
• HEERES J, BACKX LJ, VAN CUTSEM J: Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones. J. Med. Chem. (1984) 27(7):894–900.
   Google Scholar
• FAERGEMANN J: In vitro and in vivo activities of ketoconazole and itraconazole against Pityrosporum orbiculare. Antimicrob. Agents Chemother. (1984) 26(5):773–774.
   PubMedGoogle Scholar
• VAN CUTSEM J: In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. Chemotherapy (1992) 38\(Suppl. 1):3–11.
   Google Scholar
• ROBERTSON LI: Itraconazole in the treatment of widespread tinea versicolor. Clin. Exp. Dermatol (1987) 12(3):178–180.
   PubMedGoogle Scholar
• CAUWENBERGH G, DE DONCKER P, STOOPS K, DE DIER AM, GOYVAERTS H, SCHUERMANS V: Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Rev. Infect. Dis. (1987) 9\(Suppl. 1):5146–5152.
   Google Scholar
• KOSE O, BULENT TH, RIZA GA, KURUMLU Z: Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. j Dermatolog. Treat. (2002) 13(2):77–79.
   PubMed Web of Science ®Google Scholar
• BHOGAL CS, SINGAL A, BARUAH MC: Comparative efficacy of ketoconazole and fluconazole in the treatment of pityriasis versicolor: a one year follow-up study. Dermatol (2001) 28(10):535–539.
   Google Scholar
• MONTERO-GEI F, ROBLES ME, SUCHIL P: Fluconazole versus itraconazole in the treatment of tinea versicolor. Int. J. Dermatol (1999) 38(8):601–603.
   PubMedGoogle Scholar
• PARTAP R, KAUR I, CHAKRABARTI A, KUMAR B: Single-dose fluconazole versus itraconazole in pityriasis versicolor. Dermatology (2004) 208(1):55–59.
   PubMedGoogle Scholar
• FARSHCHIAN M, YAGHOOBI R, SAMADI K: Fluconazole versus ketoconazole in the treatment of tinea versicolor. j Dermatolog. Treat. (2002)13:73-76. A well-conducted and reported clinical trial.
   Google Scholar
• AMER Mk Fluconazole in the treatment of tinea versicolor. Egyptian Fluconazole Study Group. Int. J. Dermatol. (1997) 36(12):940–942.
   PubMedGoogle Scholar
• FAERGEMANN J: Pityrosporum infections. J. Am. Acad. Dermatol. (1994) 31(3 Pt 2):518–520.
   Google Scholar
• FAERGEMANN J, GUPTA AK, AL MOFADI A, ABANAMI A, SHAREAAH AA, MARYNISSEN G: Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch. Dermatol. (2002) 138(1):69–73.
   PubMedGoogle Scholar
• FAERGEMANN J, DJARV L: Tinea versicolor: treatment and prophylaxis with ketoconazole. Cutts (1982) 30(4):542–545, 550.
   Google Scholar
• RAUSCH LJ, JACOBS PH: Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutts (1984) 34(5):470–471.
   PubMed Web of Science ®Google Scholar
• VANDER STRATEN MR, HOSSAIN MA, GHANNOUM MA: Cutaneous infections dermatophytosis, onychomycosis, and tinea versicolor. Infect. Dis. Clin. North Am. (2003) 17(1):87–112.
   PubMed Web of Science ®Google Scholar
• GALIMBERTI RU, VILLALBA I, GALARZA S, RAIMONDI A, FLORES V: Itraconazole in pityriasis versicolor: ultrastructural changes in Malassezia fitrfitr produced during treatment. Rev. Infect. Dis. (1987) 9\(Suppl. 1):5134–5138.
   Google Scholar
• HICKMAN JG: A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. J. Am. Acad. Dermatol. (1996) 34(5 Pt 1):785–787.
   Google Scholar
• GUPTA AK, KATZ HI, SHEAR NH: Drug interactions with itraconazole, fluconazole, and terbinafine and their management/. Am. Acad. Dermatol. (1999) 41(2 Pt 0:237–249.
   Google Scholar
• LOMAESTRO BM, PIATEK Mk Update on drug interactions with azole antifungal agents. Ann. Pharmacother. (1998) 32(9):915–928.
   PubMedGoogle Scholar
• MICHALETS EL: Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy (1998) 18(1):84–112.
   PubMed Web of Science ®Google Scholar
• SHEAR N, DRAKE L, GUPTA AK, LAMBERT J, YANIV R: The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. Dermatology (2000) 201 (3) :196–203.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review on drug interactions involving oral antifungal agents.
   Google Scholar
• SANCHEZ JL, TORRES VM: Double-blind efficacy study of selenium sulfide in tinea versicolor. J. Am. Acad. Dermatol. (1984) 11(2 Pt 0:235–238.
   Google Scholar
• HERNANDEZ-PEREZ E: A comparison between one and two weeks' treatment with bifonazole in pityriasis versicolor. J. Am. Acad. Dermatol. (1986) 14(4):561–564.
   PubMedGoogle Scholar
• GALIMBERTI R, BELLI L, GATTI JC, NEGRONI R, VIGNALE R: An open, multicentre assessment of the effectiveness of bifonazole in the treatment of tinea (pityriasis) versicolor. Pharmatherapeutica (1985) 4(2):109–112.
   PubMedGoogle Scholar
• GALIMBERTI RU, BONINO M, FLORES Vet aL: Ultra-short topical treatment of pityriasis versicolor with 2.5% bifonazole cream. Clin. Exp. Dermatol. (1993) 18(1):25–29.
   Google Scholar
• HERNANDEZ-PEREZ E: A comparison between two different regimens of monthly application with bifonazole spray 1% in pityriasis versicolor. Int. J. Dermatol. (1990) (6):438–440.
   Google Scholar
• SAWN R, EISEN D, FRADIN MS, LEBWOHL M: Tinea versicolor treated with terbinafine 1% solution. Int. J. Dermatol. (1999) 38(11):863–865.
   PubMedGoogle Scholar
• BUDIMULJA U, PAUL C: One-week terbinafine 1% solution in pityriasis versicolor: twice-daily application is more effective than once-daily. J. Dermatolog. Treat. (2002) 13(1):39–40.
   PubMed Web of Science ®Google Scholar
• HIRA SK, DIN SN, PATEL JS: Econazole 1% in the treatment of pityriasis versicolor in Zambia. J. Am. Acad. Dermatol. (1985) 12(3):580–581.
   PubMedGoogle Scholar
• ZAIAS N, BATTISTINI F: Superficial mycoses: treatment with a new, broad-spectrum antifungal agent: 1% clotrimazole solution. Arch. Dermatol. (1977) 113(3):307–308.
   PubMedGoogle Scholar
• •A well-conducted and reported clinical trial.
   Google Scholar
• CULLEN SI, GROST P, JACOBSON C, KANDE NB: Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. Clin. Ther. (1985) 7(5):574–583.
   PubMedGoogle Scholar
• GUGNANI HC, AKPATA LE, GUGNANI MK, SRIVASTAVA R: Isoconazole nitrate in the treatment of tropical dermatomycoses. Mycoses (1994) 37(1-2):39–41.
   PubMedGoogle Scholar
• DEL P, CUETARA S, IZQUIERDO I, VIDELA S et aL: A double-blind, randomized comparative trial: flutrimazole 1% solution versus bifonazole 1% solution once daily in dermatomycoses. Mycoses (1995) 38(9-10):395–403.
   PubMedGoogle Scholar
• ALOMAR A, VIDELA S, DELGADILLO J, GICH I, IZQUIERDO I, FORN J: Flutrimazole 1% dermal cream in the treatment of dermatomycoses: a multicentre, double-blind, randomized, comparative clinical trial with bifonazole 1% cream. Efficacy of flutrimazole 1% dermal cream in dermatomycoses. Catalan Flutrimazole Study Group. Dermatology (1995) 190(4):295–300.
   Google Scholar
• FREDRIKSSON T: Treatment of dermatomycoses with topical tioconazole and miconazole. Dermatologica (1983) 166(Suppl.):114–119.
   Google Scholar
• SAWN RC: Systemic ketoconazole in tinea versicolor: a double-blind evaluation and 1-year follow-up. J. Am. Acad. Dermatol. (1984) 10(5 Pt 1):824–830.
   Google Scholar
• GIAM YC, RAJAN VS: Oral Ketoconazole-a new treatment for Tinea Versicolor. Singapore Med. J. (1984) 25 (3): 157–160.
   PubMedGoogle Scholar
• BORELLI D: Treatment of pityriasis versicolor with ketoconazole. Rev. Infect. Dis. (1980) 2(4):592–595.
   PubMedGoogle Scholar
• ALTERAS I, SANDBANK M, SEGAL R: Two years of follow-up of oral ketoconazole therapy in 60 cases of pityriasis versicolor. Dermatologica (1987) 175(3):142–144.
   PubMedGoogle Scholar
• FERNANDEZ-NAVA HD, LAYA-CUADRA B, TIANCO EA: Comparison of single dose 400 mg versus 10-day 200 mg daily dose ketoconazole in the treatment of tinea versicolor. Int. J. Dermatol. (1997) 36(1):64–66.
   PubMedGoogle Scholar
• •A well-conducted and reported clinical trial.
   Google Scholar
• GIAM YC, THAM SN: Ketoconazole in Tinea versicolor: is ten day therapy adequate? Singapore Med. J. (1987) 28(1): 13–17.
   Google Scholar
• DEL PALACIO HA, FRIAS-INIESTA J, GONZALEZ-VALUE O, BORGERS M, VAN CUTSEM J, CAUWENBERGH G: Itraconazole therapy in pityriasis versicolor. Br. J. DermatoL (1986) 115(2):217–225.
   PubMedGoogle Scholar
• •A well-conducted and reported clinical trial.
   Google Scholar
• DELESCLUSE J, CAUWENBERGH G, DEGREEF H: Itraconazole, a new orally active antifitngal, in the treatment of pityriasis versicolor. Br. J. Dermatol. (1986) 114(6):701–703.
   PubMedGoogle Scholar
• •A well-conducted and reported clinical trial.
   Google Scholar
• PANCONESI E, DIFONZO E: Treatment of dermatophytoses and pityriasis versicolor with itraconazole. Rev. Infect. Dis. (1987) 9\(Suppl. 1):S109–S113.
   Google Scholar
• ESTRADA RA: Itraconazole in pityriasis versicolor. Rev. Infect. Dis. (1987) 9\(Suppl. 1):S128–S130.
   Google Scholar
• MORALES-DORIA M: Pityriasis versicolor: efficacy of two five-day regimens of itraconazole. Rev. Infect. Dis. (1987) 9\(Suppl. 1):S131–S133.
   Google Scholar
• •A well-conducted and reported clinical trial.
   Google Scholar
• FAERGEMANN J: Treatment of pityriasis versicolor with itraconazole. Mykosen (1987) 30(1):44–47.
   PubMedGoogle Scholar
• FAERGEMANN J: Treatment of pityriasis versicolor with itraconazole: a double-blind placebo controlled study. Mycoses (1988) 31(7):377–379.
   PubMedGoogle Scholar
• •A well-conducted and reported clinical trial.
   Google Scholar
• ROSEEUW D, WILLEMSEN M, KINT RT, PEREMANS W, MERTENS RL, VAN CUTSEM J: Itraconazole in the treatment of superficial mycoses-a double-blind study versus placebo. Clin. Exp. DermatoL (1990) 15(2):101–104.
   PubMedGoogle Scholar
• •A well-conducted and reported clinical trial.
   Google Scholar
• FAERGEMANN J: Treatment of pityriasis versicolor with a single dose of fluconazole. Acta Derm. VenereoL (1992) 72(0:74–75.
   PubMedGoogle Scholar
• KOSE O: Fluconazole versus itraconazole in the treatment of tinea versicolor. Int. J. DermatoL (1995) 34(7):498–499.
   PubMedGoogle Scholar
• DEL PALACIO HA, DELGADO VS, MENENDEZ RF, RODRIGUEZ-NORIEGA BA: Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor. Rev. Infect. Dis. (1987) 9\(Suppl. 1):5121–5127.
   Google Scholar